Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.73 |
| ▸ | ITGAV | P06756 | 20/20 | 0.73 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.73 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.60 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419388 | 0.90 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6788320 | 0.90 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6789457 | 0.88 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL30856550 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL30856556 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL243383 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL983500 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL979390 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL12948919 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2050052 | 0.84 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |